|Bid||562.00 x 800|
|Ask||576.00 x 1100|
|Day's range||565.39 - 573.01|
|52-week range||441.00 - 686.62|
|Beta (5Y monthly)||0.21|
|PE ratio (TTM)||10.34|
|Earnings date||04 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||690.00|
AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.
Dr. Calvin Sun, The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.